Abstact
The present paper demonstrates that the proteasome inhibitor bortezomib, which behaves as an apoptotic agent in hepatoma HepG2 cells, caused in these cells a decrease in IκBα level and a consequent increase in NF-κB activity. The effect already appeared at 4 h of treatment and preceded the onset of apoptosis which was observed at 24 h. Our results demonstrate that bortezomib-induced IκBα degradation occurred in conjunction with the activation of caspase-8; moreover, the decrease in IκBα level was prevented in a dose-dependent manner by the addition of z-IETD, a specific inhibitor of caspase-8. Bortezomib caused the same effects in non-tumor Chang liver cells, which were not susceptible to the apoptotic effect of the drug. Our results also show that other proteases, such as caspase-3 and calpains, exerted only a limited effect on IκBα degradation. These findings suggest that caspase-8 can be involved in the control of IκBα level. In addition, the activation of caspase-8 can exert, at least in the first phase of treatment with bortezomib, a protective effect in both HepG2 and Chang liver cells, favouring the activation of the survival factor NF-κB
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shishodia S, Aggarwal BB: Nuclear factor-κB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res 119: 139–173, 2004
Kucharczak J, Simmons MJ, Fan Y, Gelinas C: To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22: 8961–8982, 2003
Chen F, Castranova V, Shi X: New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol 159: 387–397, 2001
Ghosh S, May MJ, Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Ann Rev Immunol 16: 225–260, 1998
Huxford T, Huang DB, Malek S, Ghosh G: The crystal structure of the IκBα/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell 95: 759–770, 1998
Yamamoto Y, Gaynor RB: IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci 29: 72–79, 2004
Chen F, Bower J, Leonard SS, Ding M, Lu Y, Rojanasakul Y, Kung HF, Vallyathan V, Castranova V, Shi X: Health Protective roles of NF-κB for chromium(VI)-induced cytotoxicity is revealed by expression of IκB kinase-beta mutant. J Biol Chem. 277: 3342–3349, 2002
Panwalkar A, Verstovsek S, Giles F: Nuclear factor-κB modulation as a therapeutic approach in hematologic malignancies. Cancer 100: 1578–89, 2004
Greten FR, Karin M: The IKK/NF-κB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 206: 193–199, 2004
Aggarwal BB: Nuclear factor-κB: the enemy within. Cancer Cell 6: 203–208, 2004
Bharti AC, Aggarwal BB: Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883–888, 2002
Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360, 2004
Zhang HG, Wang J, Yang X, Hsu HC, Mountz J D: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 15: 2009–2015, 2004
Colson K, Doss DS, Swift R, Tariman J, Thomas TE: Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs 8: 473–480, 2004
Dai Y, Rahmani M, Grant S: Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22: 7108–7122, 2003
An J, Sun Y, Fisher M, Rettig MB: Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther 3: 727–736, 2004
Emanuele S, Calvaruso G, Lauricella M, Giuliano M, Bellavia G, D'Anneo A, Vento R, Tesoriere G: Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3. Int J Oncol 21: 857–865, 2002
Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795–808, 1992
Lauricella M, Calvaruso G, Carabillò M, D'Anneo A, Giuliano M, Emanuele S, Vento R, Tesoriere G: pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase. FEBS Lett 499: 191–197, 2001
Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989
Rabinovich GA, Alonso CR, Sotomayor CE, Durand S, Bocco JL, Riera CM: Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ 7: 747–753, 2000
Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G: JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis, 2005, in press
Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-κB activation. J Biol Chem 274: 787–794, 1999
Scholzke MN, Potrovita I, Subramaniam S, Prinz S, Schwaninger M: Glutamate activates NF-κB through calpain in neurons. Eur J Neurosci 18: 3305–3310, 2003
Voorhees, PM, Dees, EC, O'Neil, B, Orlowski, RZ: The Proteasome as a Target for Cancer Therapy. Clin Cancer Res 9: 6316–6325, 2003
Nemeth ZH, Wong HR, Odoms K, Deitch EA, Szabo C, Vizi ES, Hasko G: Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells. Mol Pharmacol 65: 342–349, 2004
Qin Z, Wang Y, Chasea TN: A caspase-3-like protease is involved in NF-κB activation induced by stimulation of N-methyl-D-aspartate receptors in rat striatum. Brain Res Mol Brain Res 80: 111–122, 2000
Boatright KM, Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 6: 725–31, 2003
Kurland JF, Voehringer DW, Meyn RE: The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J Biol Chem 278: 32465–32470, 2003
Grimm T, Schneider S, Naschberger E, Huber J, Guenzi E, Kieser A, Reitneir P, Schulz TF, Morris CA, Sturzl M: EBV latent membrane protein-1 protects cells from apoptosis by inhibition of Bax. Blood 105: 3263–69, 2005
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calvaruso, G., Giuliano, M., Portanova, P. et al. Bortezomib induces in HepG2 cells IκBα degradation mediated by caspase-8. Mol Cell Biochem 287, 13–19 (2006). https://doi.org/10.1007/s11010-005-9016-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-9016-3